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cially as recent advances in material and production meth-
ods have created new possibilities in stent design and allow 
for the production of very thin metal stents struts.
This is of note, as the pivotal role of stent design and 
geometry on neointima formation and stent thrombosis is 
well recognised. More specifically, experimental and clini-
cal studies have confirmed again and again the importance 
of reducing stent strut thickness, with thinner struts, elicit-
ing less restenosis than thicker struts in both BMS and DES 
[3]. Thicker struts increase blood flow separation, stagnation 
and reattachment which can ultimately lead to an increased 
rate of stent thrombosis [4].
In the current issue of the Netherlands Heart Journal, 
Suttorp et al. present a result of today’s quest for optimised 
stent design and deserve to be congratulated on their work. 
The SOLSTICE registry [5] included a series of patients 
treated in four Benelux centres with the SolarFlex BMS 
(DISA Vascular, Cape Town, South Africa, CE approval 
February 2014), a balloon-expandable Cobalt Cromium 
stent with remarkable thin struts of 65 µm. The clinical out-
come up to 6 months is encouraging with a major adverse 
cardiac event (MACE) rate of 5.8 %. SOLSTICE is a reg-
istry, with all its advantages and disadvantages. The reg-
istry focuses on practical aspects such as device success. 
The patient population is more likely to reflect a real-world 
cathlab population with a considerable amount of patients 
with acute coronary syndromes (47.1 %) and diabetes 
(29 %) being included. However, relatively simple lesions 
were selected for treatment as reflected by the use of single 
stent (as per protocol), stent diameter (mean 3.1 mm), stent 
length (mean 17.4 mm) and low grade lesion angulation and 
tortuosity. Follow-up is clinical and extends up to 6 months, 
which is known to be the period when the peak of neointi-
mal growth after BMS implantation has been reached [6]. 
Importantly, no follow-up angiography has been performed, 
Coronary stenting is the preferred treatment for symptomatic 
stenotic coronary artery disease since the mid-1990s. Early 
limitations of bare metal stents (BMS), namely (sub)acute 
stent thrombosis, were relatively quickly mastered by rec-
ognising the importance of optimal stent expansion and the 
introduction of dual antiplatelet therapy. The main limitation 
affecting the long-term outcome of BMS, namely excessive 
neointima formation causing stent restenosis, was way more 
challenging. The quest for solving this problem triggered 
the proposal of a variety of strategies including intravascular 
ultrasound-guided stent optimisation, rota-stenting, brachy-
therapy and local and systemic pharmacotherapy. Finally, 
drug-eluting stents (DES) were successfully developed to 
overcome this problem at the beginning of the millennium. 
Restenosis rates have dropped dramatically since and DES 
are superior to BMS in almost every situation [1]. This had 
established DES as standard of care. While DES do not 
induce the fast neointimal growth that leads to restenosis in 
BMS typically within the first 6 months after implantation, 
we recognised a new enemy: (very) late stent failure beyond 
12 months, caused by development of early neoatheroscle-
rosis within the DES on the one hand [2] and impaired heal-
ing on the other hand. Against this background, the quest 
for improving stent technology is ongoing. The concept of 
BMS, where both neoatherosclerosis and impaired healing 
play a less apparent clinical role, is again of interest. Espe-
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which is in line with the contemporary focus on clinical out-
come (as opposed to the focus on angiographic outcome in 
the early days of BMS) and the notion that follow-up angi-
ography in itself can trigger revascularisation events. This 
‘oculo-stenotic reflex’ has been shown to potentially double 
the revascularisation rate. When comparing MACE and tar-
get-vessel revascularisation rates of contemporary studies 
with clinical follow-up of BMS studies from the past with 
mandatory angiographic follow-up, this has to be taken into 
account. The SOLSTICE registry reports a target-vessel 
failure rate of 5 % which is remarkably low for BMS. Hav-
ing said that, it would have been particularly interesting to 
gain insights into the pathophysiological mechanism of the 
stent failure cases which could further increase the knowl-
edge about the role of strut thickness in vascular response 
and how to avoid unfavourable outcome.
What can we expect in 2015—will we be back to the 
future with the renaissance of sophisticated BMS? Certainly, 
current developments in stent design make for an interesting 
time in the catheterisation laboratory. There is innovation, 
allowing the realisation of more challenging stent designs, 
both in stent geometry as well as material characteristics. 
We will be able to offer our patients ‘stents to stay’ and bio-
resorbable ‘stents to disappear’, a concept that has only just 
begun. Carefully designed mechanistic studies and clinical 
observations will be needed to determine the role and most 
appropriate indications for their use.
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